anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Anxiety is common in those with chronic physical health conditions and can have significant impacts on both quality of life and physical health outcomes. Despite this, there are limited studies comprehensively investigating the prevalence of anxiety in respiratory and sleep medicine settings. This systematic review and meta-analysis aims to provide insight into the global prevalence of anxiety symptoms/disorders in respiratory and sleep medicine outpatients.
METHODS: PubMed, Embase, Cochrane, PsycINFO and Google Scholar databases were searched from database inception to January 23, 2023 for studies assessing the prevalence of anxiety in adult (≥16 years) respiratory and sleep medicine outpatients. Data was screened and extracted independently by two investigators. Anxiety was measured using various self-report questionnaires, structured interviews, and/or patient records. Using CMA software for the meta-analysis, a random-effects model was used for pooled estimates, and subgroup analysis was conducted on relevant models using a mixed-effects model.
RESULTS: 116 studies were included, featuring 36,340 participants across 40 countries. The pooled prevalence of anxiety was 30.3 % (95%CI 27.9-32.9 %, 10,679/36,340). Subgroup analysis found a significant difference across type of condition, with pulmonary tuberculosis the highest at 43.1 % and COVID-19 outpatients the lowest at 23.4 %. No significant difference was found across anxiety types, country or age. Female sex and the use of self-report measures was associated with significantly higher anxiety estimates.
CONCLUSIONS: Anxiety is a common experience amongst patients in respiratory and sleep medicine outpatient settings. Thus, it is crucial that anxiety identification and management is considered by physicians in the field.
REGISTRATION: The protocol is registered in PROSPERO (CRD42021282416).
An alarm system for notifying necessary medical and hospital personnel that a patient or the patient's life support equipment require immediate response without providing the alarm signal to the monitored patient or surrounding patients, to prevent patient trauma which may otherwise result from the sound of the alarm. The system includes an alarm signal generator that provides a coded pulse indication of the patient and equipment type. The coded signal is sent to a master control unit preferably located at a nurses' station. The master control unit then transmits the coded alarm signal simultaneously to the appropriate group of pagers having vibrational annunciators and a visual display that describes the patient location and equipment type. The patients monitor and equipment at bedside and the pagers have no audio alarm signals. The alarm signal can only be terminated manually by an interrupt switch at the bedside.
PURPOSE:To obtain preventive and curing drug exhibiting synergistic effect and capable of suppressing protozoa disease with practically possible range of administration dose by combining plant component having antiprotozoal activity and ionophores antibiotic. CONSTITUTION:The aimed preventive and curing drug for protozoa disease is composed of (A) plant component having antiprotozoal activity, e.g. condensed type tannin, resinous glucoside, magnolol, derivative of said substances or plant body containing said substances and (B) ionophores antibiotic, e.g. monensin, narasin, salinomycin, lasalocid, carriomycin or maduramicin. Said drug is preferably administrated with adding to feed and the adding amount is suitably 0.01-1.5wt.%, preferably 0.02-1.0wt.% the component A and 1/2 amount-same amount of normally admired adding amount of ionophores antibiotic to feed of the component B. By said method, using amount of ionophores antibiotic, and also possibility of acquirement of resistance to ionophores, are able to be reduced.
BACKGROUND: Pituitary stalk interruption syndrome (PSIS) is a complex clinical syndrome characterized by varied pituitary hormone deficiencies, leading to severe manifestations across multiple systems. These include lifelong infertility, short stature, mental retardation, and potentially life-threatening pituitary crises if not promptly diagnosed and treated. Despite extensive research, the precise pathogenesis of PSIS remains unclear. Currently, there are two proposed theories regarding the pathogenic mechanisms: the genetic defect theory and the perinatal injury theory.
METHODS: We systematically searched English databases (PubMed, Web of Science, Embase) and Chinese databases (CNKI, WanFang Med Online, Sinomed) up to February 24, 2023, to summarize studies on gene sequencing in PSIS patients. Enrichment analyses of reported mutated genes were subsequently performed using the Metascape platform.
RESULTS: Our study included 37 articles. KEGG enrichment analysis revealed mutated genes were enriched in the Notch signaling pathway, Wnt signaling pathway, and Hedgehog signaling pathway. GO enrichment analysis demonstrated mutated genes were enriched in biological processes such as embryonic development, brain development, axon development and guidance, and development of other organs.
CONCLUSION: Based on our summary and analyses, we propose a new hypothesis: disruptions in normal embryonic development, partially stemming from the genetic background and/or specific gene mutations in individuals, may increase the likelihood of abnormal fetal deliveries, where different degrees of traction during delivery may lead to different levels of pituitary stalk interruption and posterior lobe ectopia. The clinical diversity observed in PSIS patients may result from a combination of genetic background, specific mutations, and variable degrees of traction during delivery.
Particular care is needed for patients who are transferred from systemically active corticosteroids to ASMANEX HFA because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although ASMANEX HFA may improve control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of corticosteroid systemically and does NOT provide the mineralocorticoid activity necessary for coping with these emergencies.

During periods of stress or severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids during periods of stress or severe asthma attack.

Patients requiring oral or other systemic corticosteroids should be weaned slowly from oral or other systemic corticosteroid use after transferring to ASMANEX HFA. Lung function (FEV1 or PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to ASMANEX HFA may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions.

During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal, e.g., joint and/or muscular pain, lassitude, and depression, despite maintenance or even improvement of respiratory function.
Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
To propose an effective action to a user.SOLUTION: An action support device supporting an action of a user so as to achieve a purpose comprises: a storage unit; an action measurement unit; and a selection unit. The storage unit stores action pattern data in which a basic action pattern in the past action pattern of a user is associated with a derivative action pattern executed by the user following the base action pattern. The action measurement unit measures the action pattern of the user. The selection unit determines whether or not a real-time action pattern of the user measured by the action measurement unit is similar to the basic action pattern in the action pattern data stored in the storage unit. The selection unit selects the derivative action pattern associated with the basic action pattern similar to the action pattern. The selection unit also outputs a recommendation of the action based on the selected derivative action pattern via an output device.SELECTED DRAWING: Figure 1
PURPOSE: To obtain a stable and aseptic ophthalmic ointment having a non- inflammatory property, etc., and useful for treating the intraocular pressure of a glaucomatous patient by adding a specified amount of a peptide ergot alkaloid in a specific form to a locally applicable ophthalmic carrier. CONSTITUTION: This ophthalmic ointment contains a peptide ergot alkaloid of the formula (R1 is H, a halogen; R2 is H, a 1-4C alkyl; R2 is isopropyl, etc.; R4 is methyl, ethyl, etc.; R5 is H; R6 is H, methoxy, etc.) in the form of a free base or acid adduct salt in a therapeutically effective amount of 0.005-0.05wt.%. The compound of the formula is preferably dihydroergotoxine, methanesulfonate, etc. The ophthalmic ointment further contains approximately 60-99.99wt.% of a hydrocarbon such as liquid paraffin or white paraffin as a locally applicable and pharmaceutically permissible carrier for eyes.
An infrared camera of the video pupillometer measures the pupillary dilation reflex (PDR) in response to incremental nociceptive stimuli. The PDR is a robust reflex, even in patients under general anesthesia, and may provide a potential evaluation of the autonomous nociceptive circuit. American Society of Anesthesiologists (ASA) classification I or II patients from the age of 28 days till 18 years undergoing elective surgery under general anesthesia are recruited. Enrolled patients perioperative undergo PDR measurement at 2 different standardized times (before and after opioid administration) generated by an inbuilt pupillary pain index (PPI) protocol. PPI, as a surrogate for nociception includes noxious stimulations from 10 up to 60 milli ampere (mA) until pupil dilation is larger than 13% from baseline diameter. Therefore, no inappropriate high stimulation is executed.
PROBLEM TO BE SOLVED: To prepare a orally administrable pharmaceutical composition excellent in collapsing characteristics by coating a formulation with a film comprising a specific film-formable polymer and a specific compound in combination. SOLUTION: This composition is obtained by dipping a tablet or a caplet into an aqueous dispersion containing a pharmaceutically acceptable and hydrophilic film-formable polymer and an alkali agent to form a film-coating. The alkali agent can increase the removing rate of the film-coating polymer and decrease the collapsing period of the film-coating. Further, when the coated tablet is brought into contact with the gastic acid, the gastic acid immediately reacts with the alkali agent, forms many holes in the film, and starts collapsing of the tablet core by penetrating the coating. The alkali agent is exemplified by sodium hydrogencarbonate. The film-formable polymer is exemplified by hydroxypropylmethylcellulose, methylcellulose, povidone and lactose.
For subjects assigned to the imaging-aided VT ablation arm, CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This integrated mapping of VT substrates sites to be ablated will be given to the electrophysiologist prior to the ablation.
The invention discloses a preparation method of a modified product of ginkgolic acid (C13: 0) and dehydroabietylamine with anticancer activity, namely an amide compound of ginkgolic acid and application of the amide compound in the aspect of anticancer activity. The preparation method of the amide compound is easy to operate. The combination of active compounds in two economic forest species is innovative. Its IC on Hela cells 50 IC value of 1.83. mu.M for HepG2 cells 50 IC value of 3.31. mu.M for MCF-7 cells 50 IC for A549 cells with a value of 9.98. mu.M 50 The value was 5.80. mu.M. Has better activity of resisting Hela cells, HepG2 cells, MCF-7 cells and A549 cells, has less toxicity, and changes the traditional concept that gingko is toxicThe phenomenon that the raw or excessive eating can cause anaphylactic reaction and even death and the like provides a new idea for the development of anti-cancer drugs. The compound has novel structure and contains long-chain electron-donating groups (-C) 13 H 27 ) The compound has low toxicity and unique anticancer activity, is an anticancer medicament with excellent prospect, creates conditions for researching the relation between the anticancer activity and the structure of the compound and lays a foundation for the research and development of new drugs.
PURPOSE: To evaluate the diagnostic performance of radiomics models derived from multi-phase spleen CT for high-risk esophageal varices (HREV) in cirrhotic patients.
METHODS: We retrospectively selected cirrhotic patients with esophageal varices from two hospitals from September 2019 to September 2023. Patients underwent non-contrast and contrast-enhanced CT scans and were categorized into HREV and non-HREV groups based on endoscopic evaluations. Radiomics features were extracted from spleen CT images in non-contrast, arterial, and portal venous phases, with feature selection via lasso regression and Pearson's correlation. Ten machine learning models were developed to diagnose HREV, evaluated by area under the curve (AUC). The AUC values of the three groups of models were statistically compared by the Kruskal-Wallis H test and Bonferroni-corrected Mann-Whitney U test. A p-value less than 0.05 was considered statistically significant.
RESULTS: Among 233 patients, 11, 6, and 11 features were selected from non-contrast, arterial, and portal venous phases, respectively. Significant differences in AUC values were observed across phases (p < 0.05), and the arterial phase models showed the highest AUC values. The best model in arterial phase was the logical regression model, whose AUC value was 0.85, sensitivity was 83.3%, specificity was 80% and F1 score was 0.81.
CONCLUSION: Radiomics models based on spleen CT, especially the arterial phase models, demonstrate high diagnostic accuracy for HREV, offering the potential for early detection and intervention.
The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
This report describes a male in his late 20s who presented with a 2-month history of recurrent haemoptysis and chest pain. A chronic infection, such as tuberculosis, was suspected. He had undergone surgical resection of an intrapericardial hydatid cyst in the past. His blood investigations showed peripheral eosinophilia, and his chest X-ray showed a cystic oval lesion in the left upper zone. A CT pulmonary angiogram revealed filling defects in the bilateral segmental and subsegmental arteries with a cystic lesion in the left upper lobe. Further workup, including bronchoalveolar lavage culture and MRI of the thorax, confirmed the diagnosis of a hydatid cyst of pulmonary echinococcosis. This case illustrates the presentation of multisystemic echinococcosis in a young male with no other risk factors, initially treated with surgical resection and antihelminthic therapy. The disease later recurred, which required prolonged medications, which brought the patient into remission.
An estimated 8 million individuals in America are affected by peripheral arterial disease (PAD). One of its extreme expressions is Critical Limb Ischemia (CLI). It is one of the most severe vascular conditions associated with devastating outcomes, including poorly healing wounds, extreme pain, and a high amputation risk. It is also one of the deadliest conditions, with 6-month and 5-year mortality rates estimated to be 20 and \>50%, respectively. To date, however, there is a paucity of prospective clinical evidence about the variability in patients' presentations, their management or their outcomes. Accordingly, little progress has been made in adequately staging the disease and to risk-stratify treatment approaches to patients' individual characteristics. What is desperately needed to advance the care and management of patients with CLI is a focused research effort to set new standards for diagnosing, describing detailed patient-centered outcomes, and evaluating the variability in therapeutic approaches and their association with outcomes. The specific aims of SCOPE-CLI are to generate new evidence on the clinical characteristics, treatment patterns and outcomes of patients with critical limb ischemia (CLI); to describe treatment patterns and variability across practices to identify gaps in delivering quality care; and to perform a series of analyses to examine the associations of patient and treatment characteristics with outcomes. The central objective of SCOPE-CLI is to systematically quantify patients' CLI-specific health status and clinical outcomes and to perform subgroup analyses as a function of different PAD treatments and patient characteristics.
Dose Level 3: AMXT-1501 RP2D and DFMO 1.5 g/m2 IV (intravenous) daily. Each patient will receive DFMO by continuous infusion pump at the dose determined by their assigned dose level in addition to the AMXT-1501. At least three and up to six patients per dose level with an estimated three dose levels (based on safety), as well as a confirmation group of the final dose may be enrolled for a projected total of 12 to 24 patients in the Phase I. Subjects may continue to receive this combination until progression or twenty-four (24), 28-day cycles, whichever occurs first.
Reactivity between an alloantigen and an anti-alloantigen is indicative of immunological reactivity between two biological samples of the same species.  Reactivity between a xenoantigen and an anti-xenoantigen is indicative of immunological reactivity between two biological samples of different species.  In many cases both of the reactions are indicative of an antibody-mediated rejection. Anti-antibodies can be employed to reduce cross-reactivity in many transplantation-type situations, either within a similar species, or across species lines. These anti-antibodies are prepared against the antibodies responsible for the antibody-mediated rejection. These anti-antibodies can then be used in vivo or in vitro to complex with the antibodies thus reducing or eliminating reactivity between an alloantigen and an anti-alloantigen or reactivity between a xenoantigen and an anti-xenoantigen between any two species combinations. These antibodies may also be used to target and eliminate the B-cells that produce anti-xenogenic antibodies.
Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
OBJECTIVES: I. Compare the incidence of acute graft versus host disease (GVHD) grades II-IV and extensive chronic GVHD in chronic myeloid leukemia patients treated with purged donor lymphocyte infusion (DLI) processed with CD8 high density microparticles (HDM) vs unpurged DLI following nonmyeloablative, HLA identical sibling peripheral blood stem cell transplantation. II. Compare the rates of complete cytogenetic, clinical, and hematologic remission and mortality and GVHD in patients treated with these regimens. III. Determine the efficacy of CD8 HDM in depleting greater than 95% of CD8+ cells in donor lymphocytes. IV. Compare the safety and toxicity of these regimens in these patients.

OUTLINE: This is a randomized, double blind, multicenter study. Patients are stratified by age (under 60 vs 60 and over) and center. Allogeneic peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells on days 5-8. Nonmyeloablative conditioning: Patients receive fludarabine IV over 30 minutes and cytarabine IV over 4 hours (beginning 4 hours after the start of fludarabine infusion) on days -6 to -3 and idarubicin IV over 1-5 minutes on days -6 to -4. Filgrastim (G-CSF) is administered subcutaneously daily beginning on day -2 and continues until blood counts recover. Graft versus host disease prevention: Beginning on day -2, patients receive tacrolimus IV continuously until oral dosing is tolerated. Patients receive tacrolimus in combination with methotrexate on days 1, 3, and 6 after completion of transplantation. Beginning 12 weeks after completion of transplantation, oral tacrolimus is tapered and stopped over 4 weeks. Transplantation: Allogeneic PBSC are infused on day 0. At 4 months posttransplantation, patients with residual Ph+ cells by cytogenetics or FISH OR hematologic or clinical evidence of chronic myeloid leukemia AND without symptomatic chronic graft versus host disease requiring immunosuppressive therapy are randomized to 1 of 2 treatment arms: Arm I: Lymphocytes harvested from the original PBSC donor are processed with the CD8 high density microparticle device to remove all or most CD8+ cells. Patients receive CD8+ cell depleted donor lymphocyte infusion (DLI) IV over 15-30 minutes on the same day of collection. Arm II: Lymphocytes are harvested from the original PBSC donor. Patients receive undepleted DLI IV over 15-30 minutes on the same day of collection. Patients are followed at days 30, 60, 100, and 180, and then periodically through year 5.

PROJECTED ACCRUAL: A maximum of 110 patients (55 per arm) will be accrued for this study within 1 year.
RT is delivered in the morning. After 4-6 hrs, C/T is applied.